Skip to main content
SpringerLink
Log in

Ponatinib Induced Stroke

  • Chapter
  • First Online:
Clinical Cases in Cardio-Oncology

Part of the book series: Clinical Cases in Cardiology ((CCC))

  • 323 Accesses

Abstract

A 55-year-old male with BCR-ABL1 T315I-positive CML in chronic phase, resistant to dasatinib and nilotinib treatment, was started on ponatinib (45 mg once daily) prior to allogeneic stem cell transplant. Within 2 weeks of initiation of therapy, he developed left sided hemiplegia and hemiparesis and was diagnosed with Middle cerebral artery (MCA) stroke. He did require extensive Neurology Rehabilitation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gambacorti-Passerini C, Piazza R. Choosing the right TKI for chronic myeloid leukemia: when the truth lies in “long-term” safety and efficacy. Am J Hematol. 2011;86(7):531–2. https://doi.org/10.1002/ajh.22084.

    Article  PubMed  Google Scholar 

  2. Dahlén T, Edgren G, Lambe M, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016;165:161.

    Article  Google Scholar 

  3. Cortes JE, Kim DW, Pinilla-Ibarz J, leCoutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1.

    Article  Google Scholar 

  4. Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25(5):482–94.

    Article  Google Scholar 

  5. Massaro F, Molica M, Breccia M. Ponatinib: a review of efficacy and safety. Curr Cancer Drug Targets. 2018;18(9):847–56.

    Article  CAS  Google Scholar 

  6. Singh AP, Glennon MS, Umbarkar P, et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc Res. 2019;115(5):966–77.

    Article  CAS  Google Scholar 

  7. Santoro M, Accurso V, Mancuso S, et al. Management of ponatinib in patients with chronic myeloid leukemia with cardiovascular risk factors. Chemotherapy. 2019;64(4):205–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northern Ontario School of Medicine, Thunder Bay, ON, Canada

    Atooshe Rohani

Authors
  1. Atooshe Rohani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atooshe Rohani .

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rohani, A. (2021). Ponatinib Induced Stroke. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71155-9_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71154-2

  • Online ISBN: 978-3-030-71155-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation